乙酸-(4-碘-2-甲基-苯基酯) | 855354-81-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 中文名称: 乙酸-(4-碘-2-甲基-苯基酯)
• 英文名称: acetic acid-(4-iodo-2-methyl-phenyl ester)
• 英文别名: Essigsaeure-(4-jod-2-methyl-phenylester)；methyl-4-iodo-phenyl acetate；Methyl-4-iodophenyl acetate；(4-iodo-2-methylphenyl) acetate
• CAS: 855354-81-3
• 化学式: C₉H₉IO₂
• 分子量: 276.074
• InChiKey: SCOOSRODDFLXCK-UHFFFAOYSA-N

物化性质

• 熔点：
  55-56 °C
• 沸点：
  281.5±28.0 °C(Predicted)
• 密度：
  1.669±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  乙酸-(4-碘-2-甲基-苯基酯) 在 sodium hydroxide 作用下， 生成 4-碘-2-甲基苯甲醚
  参考文献：
  名称：

  The Synthesis and Properties of some Alkyliodophenols

  摘要：

  DOI：

  10.1021/jo50001a014
• 作为产物：
  描述：

  乙酸-2-甲基苯基酯 在 硬脂醇聚醚-10 作用下， 生成 乙酸-(4-碘-2-甲基-苯基酯)
  参考文献：
  名称：

  The Synthesis and Properties of some Alkyliodophenols

  摘要：

  DOI：

  10.1021/jo50001a014

文献信息

• [EN] METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B<br/>[FR] PROCEDES PERMETTANT DE TRAITER DES TROUBLES SENSIBLES AU RETINOIDE AU MOYEN D'INHIBITEURS SELECTIFS DE CYP26A ET DE CYP26B
  申请人：ALLERGAN INC

  公开号：WO2005058301A1

  公开（公告）日：2005-06-30

  The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.

  本发明提供了一种治疗患有视黄酸反应性障碍的个体的方法。在一个实施例中，一种方法包括向个体施用有效量的选择性CYP26B抑制剂，所述选择性CYP26B抑制剂相对于CYP26A至少具有10倍的选择性。在另一个实施例中，一种方法包括向个体施用有效量的选择性CYP26A抑制剂，所述选择性CYP26A抑制剂的化学公式如说明书所述。本发明还提供了用于识别选择性CYP26A抑制剂或选择性CYP26B抑制剂的筛选方法。
• Compounds having activity as inhibitors of cytochrome P450RAI
  申请人：——

  公开号：US20020183285A1

  公开（公告）日：2002-12-05

  Compounds having Formulas 5 and 6 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids. 1

  化合物式为5和6的复合物，其中符号的含义在说明书中有定义，是细胞色素P450RAI（诱导维甲酸）酶的抑制剂，用于治疗对维甲酸类药物治疗敏感的疾病。
• Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
  申请人：——

  公开号：US20030078270A1

  公开（公告）日：2003-04-24

  Novel compounds having the Formulas 1 through 8, wherein the symbols have the meaning defined in the specification, and certain previously known compounds have been discovered to act as inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids. The compound can also be used in co-treatment with retinoids. 1

  具有1到8式的新化合物已被发现可以作为细胞色素P450RAI（诱导维甲酸）酶的抑制剂，并用于治疗对维甲酸类治疗有反应的疾病。该化合物还可与维甲酸类药物共同治疗。其中符号的含义在说明中定义。
• Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
  申请人：Vasudevan Jayasree

  公开号：US20050176689A1

  公开（公告）日：2005-08-11

  Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.

  本说明书提供的1至17式化合物可以特异性地抑制细胞色素P450RAI-1酶或细胞色素P450RAI-2酶。
• Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B
  申请人：Vasudevan Jayasree

  公开号：US20050187298A1

  公开（公告）日：2005-08-25

  The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.

  本发明提供了治疗具有视黄醇响应性疾病的个体的方法。在一种实施方式中，该方法涉及向个体施用有效量的选择性CYP26B抑制剂，该选择性CYP26B抑制剂相对于CYP26A具有至少10倍的选择性。在另一种实施方式中，该方法涉及向个体施用有效量的选择性CYP26A抑制剂，该选择性CYP26A抑制剂具有在规范中列出的化学式。本发明还提供了筛选方法，用于识别选择性CYP26A抑制剂或选择性CYP26B抑制剂。